 |
|
|
|
|
|
|
|
|
|
|
 |
|
|||||||||
 |
 |
 |
 |
 |
 |
 |
 |
|
||
 |
 |
 |
|
|||||||
 |
|
|||||||||
 |
|
|||||||||
Alert Number 153
Date: March 5, 2024
More than two years ago, PC and I were invited to attend an advocacy meeting at the headquarters of Genitope Corp. Genitope is one of a few companies that has interesting vaccine technology for B-cell cancers. I am happy to report Genitope has just launched their vaccine trial for early stage and chemo naïve CLL patients. The latest article on our website, A Vaccine Trial for CLL Patients, reviews the design of the Genitope clinical trial and considers the pros and cons. While I am delighted to see this important clinical trial is finally open for patient recruitment, I wish the trial's inclusion criteria were a little broader, so that more patients would be eligible to participate.
I think this trial will finish recruitment rather quickly. If you are interested and you fit the inclusion criteria, you should get on the horn to Genitope sooner rather than later. You can get the contact information and a whole lot more from our review of this trial. Tell them CLL Topics sent you.
Be well,
Chaya
________
NOTICE: This page from the Topics Alert archive was originally emailed to subscribers of Topics Alert, a free service of CLL Topics Inc. If you are not a subscriber and you wish to receive email Alerts, please register at the Topics Alert subscription page. The content of this page is intended for information only and it is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
———
Disclaimer: The content of this website is intended for information only and is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
Copyright Notice:
Copyright © 2024-2007 CLL Topics, Inc. All Rights Reserved.
All materials contained on this site are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, published or broadcast without the prior written permission of CLL Topics, Inc. You may not alter or remove any trademark, copyright or other notice from copies of the content.
However, you may download and print material from CLLTopics.org exclusively for your personal, noncommercial use.
———
